ClinicalTrials.gov
public full text
Public Domain
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in patients with advanced malignant tumors
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of LM-24C5 For Advanced Solid Tumors#916439
- A Study of LM-350 in Subjects With Advanced Solid Tumours#1032350
- Study of LM-102 in Subjects in Advanced Tumors#906800
- A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours#870777
- A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors#1073610
Record · ID 885989
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive